These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 38008193)
21. Current Strategies of Antiviral Drug Discovery for COVID-19. Mei M; Tan X Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887 [TBL] [Abstract][Full Text] [Related]
22. High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system. Lee N; Shum D; König A; Kim H; Heo J; Min S; Lee J; Ko Y; Choi I; Lee H; Radu C; Hoenen T; Min JY; Windisch MP Antiviral Res; 2018 Oct; 158():226-237. PubMed ID: 30149038 [TBL] [Abstract][Full Text] [Related]
23. Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model. Everts M; Cihlar T; Bostwick JR; Whitley RJ Annu Rev Pharmacol Toxicol; 2017 Jan; 57():155-169. PubMed ID: 27483339 [TBL] [Abstract][Full Text] [Related]
24. A high-content screening (HCS) assay for the identification of chemical inducers of PML oncogenic domains (PODs). Yip KW; Cuddy M; Pinilla C; Giulanotti M; Heynen-Genel S; Matsuzawa S; Reed JC J Biomol Screen; 2011 Feb; 16(2):251-8. PubMed ID: 21233309 [TBL] [Abstract][Full Text] [Related]
26. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries. David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A Molecules; 2021 May; 26(11):. PubMed ID: 34072087 [TBL] [Abstract][Full Text] [Related]
27. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527 [TBL] [Abstract][Full Text] [Related]
28. High-throughput screening assays for SARS-CoV-2 drug development: Current status and future directions. Xu T; Zheng W; Huang R Drug Discov Today; 2021 Oct; 26(10):2439-2444. PubMed ID: 34048893 [TBL] [Abstract][Full Text] [Related]
29. Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections. Dos Santos Nascimento IJ; de Aquino TM; da Silva-Júnior EF Curr Med Chem; 2021; 28(15):2887-2942. PubMed ID: 32787752 [TBL] [Abstract][Full Text] [Related]
30. A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects. Doijen J; Heo I; Temmerman K; Vermeulen P; Diels A; Jaensch S; Burcin M; Van den Broeck N; Raeymaekers V; Peremans J; Konings K; Clement M; Peeters D; Van Loock M; Koul A; Buyck C; Van Gool M; Van Damme E Antiviral Res; 2024 Feb; 222():105789. PubMed ID: 38158129 [TBL] [Abstract][Full Text] [Related]
31. Structure of M Jin Z; Du X; Xu Y; Deng Y; Liu M; Zhao Y; Zhang B; Li X; Zhang L; Peng C; Duan Y; Yu J; Wang L; Yang K; Liu F; Jiang R; Yang X; You T; Liu X; Yang X; Bai F; Liu H; Liu X; Guddat LW; Xu W; Xiao G; Qin C; Shi Z; Jiang H; Rao Z; Yang H Nature; 2020 Jun; 582(7811):289-293. PubMed ID: 32272481 [TBL] [Abstract][Full Text] [Related]
32. Commercial SARS-CoV-2 Targeted, Protease Inhibitor Focused and Protein-Protein Interaction Inhibitor Focused Molecular Libraries for Virtual Screening and Drug Design. Kralj S; Jukič M; Bren U Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008818 [TBL] [Abstract][Full Text] [Related]
33. Human monoclonal antibodies as candidate therapeutics against emerging viruses. Jin Y; Lei C; Hu D; Dimitrov DS; Ying T Front Med; 2017 Dec; 11(4):462-470. PubMed ID: 29159596 [TBL] [Abstract][Full Text] [Related]
34. A High-Throughput, High-Containment Human Primary Epithelial Airway Organ-on-Chip Platform for SARS-CoV-2 Therapeutic Screening. Fisher CR; Mba Medie F; Luu RJ; Gaibler RB; Mulhern TJ; Miller CR; Zhang CJ; Rubio LD; Marr EE; Vijayakumar V; Gabriel EP; Lopez Quezada L; Zhang CH; Anderson KS; Jorgensen WL; Alladina JW; Medoff BD; Borenstein JT; Gard AL Cells; 2023 Nov; 12(22):. PubMed ID: 37998374 [TBL] [Abstract][Full Text] [Related]
35. Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro. Raymonda MH; Ciesla JH; Monaghan M; Leach J; Asantewaa G; Smorodintsev-Schiller LA; Lutz MM; Schafer XL; Takimoto T; Dewhurst S; Munger J; Harris IS Virology; 2022 Jan; 566():60-68. PubMed ID: 34871905 [TBL] [Abstract][Full Text] [Related]
36. Neutralization of SARS-CoV-2 Spike Protein via Natural Compounds: A Multilayered High Throughput Virtual Screening Approach. Dhasmana A; Kashyap VK; Dhasmana S; Kotnala S; Haque S; Ashraf GM; Jaggi M; Yallapu MM; Chauhan SC Curr Pharm Des; 2020; 26(41):5300-5309. PubMed ID: 32867645 [TBL] [Abstract][Full Text] [Related]
37. Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing. He X; Quan S; Xu M; Rodriguez S; Goh SL; Wei J; Fridman A; Koeplinger KA; Carroll SS; Grobler JA; Espeseth AS; Olsen DB; Hazuda DJ; Wang D Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33766889 [TBL] [Abstract][Full Text] [Related]